Ginkgo Bioworks Holdings (DNA) Gains from Investment Securities (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Gains from Investment Securities of $19000.0 for Q1 2026, down 88.62% year-on-year from $167000.0 in Q1 2025, and up 106.42% on a QoQ basis from -$296000.0 in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Gains from Investment Securities data on file, last reported at $19000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 88.62% year-over-year to $19000.0; the trailing twelve-month figure through Mar 2026 stood at -$277000.0 (up 93.17% YoY), and the FY2025 full-year result was -$296000.0, changed N/A from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $19000.0, up from -$296000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $97.3 million in Q4 2022 and bottomed at -$3.2 million in Q2 2024.
- The 5-year median for Gains from Investment Securities is $19000.0 (2026), against an average of $9.2 million.
- Peak annual rise in Gains from Investment Securities reached 684.78% in 2024, while the deepest fall reached 172.13% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $97.3 million in 2022, then plunged by 100.09% to -$92000.0 in 2023, then surged by 684.78% to $538000.0 in 2024, then slumped by 155.02% to -$296000.0 in 2025, then soared by 106.42% to $19000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $19000.0 (Q1 2026), -$296000.0 (Q4 2025), and $167000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,000.00 |
| Mar 31, 2026 | 19,000.00 |
| Dec 31, 2025 | -296,000.00 |
| Dec 31, 2025 | -296,000.00 |
| Mar 31, 2025 | 167,000.00 |
| Mar 31, 2025 | 167,000.00 |
| Dec 31, 2024 | 538,000.00 |
| Dec 31, 2024 | 538,000.00 |
| Sep 30, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | -3.23 Mn |
| Jun 30, 2024 | -3.23 Mn |
| Dec 31, 2023 | -92,000.00 |
| Dec 31, 2023 | -92,000.00 |
| Sep 30, 2023 | -1.89 Mn |
| Sep 30, 2023 | -1.89 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Mar 31, 2023 | -1.12 Mn |
| Mar 31, 2023 | -1.12 Mn |
| Dec 31, 2022 | 97.34 Mn |
| Dec 31, 2022 | 97.34 Mn |
| Sep 30, 2022 | 17.32 Mn |
| Sep 30, 2022 | 17.32 Mn |
| Mar 31, 2022 | 8.03 Mn |
| Mar 31, 2022 | 8.03 Mn |
| Dec 31, 2021 | -48.90 Mn |
| Dec 31, 2021 | -48.90 Mn |
| Sep 30, 2021 | 18.48 Mn |
| Sep 30, 2021 | 18.48 Mn |
| Dec 31, 2020 | -16.93 Mn |
| Dec 31, 2020 | -16.93 Mn |